Sees FY24 adjusted EBITDA $20M-$23M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Optimistic Financial and Strategic Outlook
- Aquestive Therapeutics, Inc. (AQST) Q3 Earnings Cheat Sheet
- Aquestive to present subsequent analysis of data from Anaphylm study
- Aquestive announces primary, secondary endpoints met in OAS challenge study
- Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study